Xenon Pharmaceuticals
XENE
103 hedge funds and large institutions have $671M invested in Xenon Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 4 closing their positions.
493% more call options, than puts
Call options by funds: $3.86M | Put options by funds: $652K
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
14% more capital invested
Capital invested by funds: $590M → $671M (+$80.7M)
13% more funds holding
Funds holding: 91 → 103 (+12)
0.2% less ownership
Funds ownership: 82.14% → 81.94% (-0.2%)
6% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$21.5M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$15.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$15.1M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$13.2M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$7.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$35.2M |
| 2 |
O
OrbiMed
New York
|
-$21.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.9M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$8.74M |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$1.25M |
XENE Hedge Fund Activity: Q2 2021 in Review
103 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2021, worth a combined $671M — up 14% from $590M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new XENE positions and 4 closed out — a net gain of 12 holders — while 29 added to existing stakes and 31 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $21.5M. The largest seller was BVF Inc, cutting an estimated $35.2M.
- 103 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2021, up from 91 in Q1 2021.
- Funds reported $671M of Xenon Pharmaceuticals stock for Q2 2021, up 14% quarter-over-quarter.
- 16 funds opened new Xenon Pharmaceuticals positions in Q2 2021 and 4 closed out, a net change of +12 holders.
- The largest Xenon Pharmaceuticals buyer in Q2 2021 was Perceptive Advisors, an estimated $21.5M added.
- The largest Xenon Pharmaceuticals seller in Q2 2021 was BVF Inc, an estimated $35.2M sold.
Based on aggregated 13F filings for Q2 2021.